109 related articles for article (PubMed ID: 21362795)
1. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy.
Lahita RG; Vernace MA
J Rheumatol; 2011 Mar; 38(3):579-80. PubMed ID: 21362795
[No Abstract] [Full Text] [Related]
2. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
3. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
4. Tuberculosis after anti-TNF therapy: a continuous learning process.
Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
[No Abstract] [Full Text] [Related]
5. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
6. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
7. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
[TBL] [Abstract][Full Text] [Related]
8. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
[No Abstract] [Full Text] [Related]
10. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
11. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
12. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
13. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
[No Abstract] [Full Text] [Related]
14. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
[No Abstract] [Full Text] [Related]
15. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
16. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
Goncalves DP; Laurindo I; Scheinberg MA
J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
[No Abstract] [Full Text] [Related]
17. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
18. Optic neuritis in a psoriatic arthritis patient treated by infliximab.
Minami-Hori M; Tsuji H; Takahashi H; Hanada K; Iizuka H
J Dermatol; 2013 Apr; 40(4):298-9. PubMed ID: 23289758
[No Abstract] [Full Text] [Related]
19. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
[No Abstract] [Full Text] [Related]
20. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.
Richette P; Dieudé P; Damiano J; Lioté F; Orcel P; Bardin T
J Rheumatol; 2004 Oct; 31(10):2079-81. PubMed ID: 15468380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
